KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

Juan Esteban Garcia-Robledo; Rafael Rosell; Alejandro Ruíz-Patiño; Carolina Sotelo; Oscar Arrieta; Lucia Zatarain-Barrón; Camila Ordoñez; Elvira Jaller; Leonardo Rojas; Alessandro Russo; Diego de Miguel-Pérez; Christian Rolfo; Andrés F. Cardona

doi:10.1177/17534666211066064

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

Juan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Camila Ordoñez, Elvira Jaller, Leonardo Rojas, Alessandro Russo, Diego de Miguel-Pérez, Christian Rolfo, Andrés F. Cardona

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.

Original language	English
Journal	Therapeutic Advances in Respiratory Disease
Volume	16
DOIs	https://doi.org/10.1177/17534666211066064
State	Published - Jan 2022
Externally published	Yes

Keywords

KRAS
MET
biomarker
directed therapy
genomic profiling
non-small-cell lung cancer
resistance
targeted therapy
tumor genomics

Access to Document

10.1177/17534666211066064

Cite this

Garcia-Robledo, J. E., Rosell, R., Ruíz-Patiño, A., Sotelo, C., Arrieta, O., Zatarain-Barrón, L., Ordoñez, C., Jaller, E., Rojas, L., Russo, A., de Miguel-Pérez, D., Rolfo, C., & Cardona, A. F. (2022). KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block. Therapeutic Advances in Respiratory Disease, 16. https://doi.org/10.1177/17534666211066064

@article{97cd26d2cb62455e8bf89133162613b0,

title = "KRAS and MET in non-small-cell lung cancer: two of the new kids on the {\textquoteleft}drivers{\textquoteright} block",

abstract = "Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor{\textquoteright}s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.",

keywords = "KRAS, MET, biomarker, directed therapy, genomic profiling, non-small-cell lung cancer, resistance, targeted therapy, tumor genomics",

author = "Garcia-Robledo, {Juan Esteban} and Rafael Rosell and Alejandro Ru{\'i}z-Pati{\~n}o and Carolina Sotelo and Oscar Arrieta and Lucia Zatarain-Barr{\'o}n and Camila Ordo{\~n}ez and Elvira Jaller and Leonardo Rojas and Alessandro Russo and {de Miguel-P{\'e}rez}, Diego and Christian Rolfo and Cardona, {Andr{\'e}s F.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2022.",

year = "2022",

month = jan,

doi = "10.1177/17534666211066064",

language = "English",

volume = "16",

journal = "Therapeutic Advances in Respiratory Disease",

issn = "1753-4658",

publisher = "SAGE Publications Ltd",

}

Garcia-Robledo, JE, Rosell, R, Ruíz-Patiño, A, Sotelo, C, Arrieta, O, Zatarain-Barrón, L, Ordoñez, C, Jaller, E, Rojas, L, Russo, A, de Miguel-Pérez, D, Rolfo, C & Cardona, AF 2022, 'KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block', Therapeutic Advances in Respiratory Disease, vol. 16. https://doi.org/10.1177/17534666211066064

TY - JOUR

T1 - KRAS and MET in non-small-cell lung cancer

T2 - two of the new kids on the ‘drivers’ block

AU - Garcia-Robledo, Juan Esteban

AU - Rosell, Rafael

AU - Ruíz-Patiño, Alejandro

AU - Sotelo, Carolina

AU - Arrieta, Oscar

AU - Zatarain-Barrón, Lucia

AU - Ordoñez, Camila

AU - Jaller, Elvira

AU - Rojas, Leonardo

AU - Russo, Alessandro

AU - de Miguel-Pérez, Diego

AU - Rolfo, Christian

AU - Cardona, Andrés F.

N1 - Publisher Copyright: © The Author(s), 2022.

PY - 2022/1

Y1 - 2022/1

N2 - Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.

AB - Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.

KW - KRAS

KW - MET

KW - biomarker

KW - directed therapy

KW - genomic profiling

KW - non-small-cell lung cancer

KW - resistance

KW - targeted therapy

KW - tumor genomics

UR - http://www.scopus.com/inward/record.url?scp=85123905646&partnerID=8YFLogxK

U2 - 10.1177/17534666211066064

DO - 10.1177/17534666211066064

M3 - Review article

C2 - 35098800

AN - SCOPUS:85123905646

SN - 1753-4658

VL - 16

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

ER -

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

Abstract

Keywords

Access to Document

Fingerprint

Cite this